ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för plinabulin. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

21 träffar

Bibliografisk träff 2022-02-18

From the North Sea to Drug Repurposing, the Antiseizure Activity of Halimide and Plinabulin.

Copmans D, Kildgaard S, Roux E, Partoens M, Steurs G, Wang X, De Borggraeve WM, Esguerra CV, Crawford AD, Larsen TO, de Witte PAM.

Pharmaceuticals (Basel) · research-article; journal article · DOI 10.3390/ph15020247

Bibliografisk träff 2022-01-04

Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Docetaxel-Induced Neutropenia in Patients With Solid Tumors: A Randomized Clinical Trial.

Blayney DW, Mohanlal R, Adamchuk H, Kirtbaya DV, Chen M, Du L, Ogenstad S, Ginn G, Huang L, Zhang Q.

JAMA Netw Open · clinical trial, phase iii; equivalence trial; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1001/jamanetworkopen.2021.45446

Bibliografisk träff 2021-03-03

Plinabulin, a Distinct Microtubule-Targeting Chemotherapy, Promotes M1-Like Macrophage Polarization and Anti-tumor Immunity.

Natoli M, Herzig P, Pishali Bejestani E, Buchi M, Ritschard R, Lloyd GK, Mohanlal R, Tonra JR, Huang L, Heinzelmann V, Trüb M, Zippelius A, Kashyap AS.

Front Oncol · research-article; journal article · DOI 10.3389/fonc.2021.644608

Bibliografisk träff 2020-11-12

Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults With Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.

Blayney DW, Zhang Q, Feng J, Zhao Y, Bondarenko I, Vynnychenko I, Kovalenko N, Nair S, Ibrahim E, Udovista DP, Mohanlal R, Ogenstad S, Ette E, Du L, Huang L, Shi YK.

JAMA Oncol · clinical trial, phase ii; research-article; randomized controlled trial; journal article · DOI 10.1001/jamaoncol.2020.4429

Bibliografisk träff 2019-12-06

Plinabulin ameliorates neutropenia induced by multiple chemotherapies through a mechanism distinct from G-CSF therapies.

Tonra JR, Lloyd GK, Mohanlal R, Huang L.

Cancer Chemother Pharmacol · brief-report; research support, non-u.s. gov't; journal article · DOI 10.1007/s00280-019-03998-w

Bibliografisk träff 2019-11-11

Development of novel phenoxy-diketopiperazine-type plinabulin derivatives as potent antimicrotubule agents based on the co-crystal structure.

Ding Z, Ma M, Zhong C, Wang S, Fu Z, Hou Y, Liu Y, Zhong L, Chu Y, Li F, Song C, Wang Y, Yang J, Li W.

Bioorg Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmc.2019.115186

Bibliografisk träff 2019-03-20

Polymorphs, co-crystal structure and pharmacodynamics study of MBRI-001, a deuterium-substituted plinabulin derivative as a tubulin polymerization inhibitor.

Ma M, Ding Z, Wang S, Ma L, Wang Y, Zhong L, Li Z, Yang J, Li W.

Bioorg Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmc.2019.03.035

Bibliografisk träff 2019-03-05

Plinabulin, an inhibitor of tubulin polymerization, targets KRAS signaling through disruption of endosomal recycling.

Cimino PJ, Huang L, Du L, Wu Y, Bishop J, Dalsing-Hernandez J, Kotlarczyk K, Gonzales P, Carew J, Nawrocki S, Jordan MA, Wilson L, Lloyd GK, Wirsching HG.

Biomed Rep · research-article; journal article · DOI 10.3892/br.2019.1196

Bibliografisk träff 2018-08-04

In vitro and in vivo pharmacokinetic and pharmacodynamic study of MBRI-001, a deuterium-substituted plinabulin derivative as a potent anti-cancer agent.

Ma M, Zhao J, Cheng H, Deng M, Ding Z, Hou Y, Li F, Dou G, Li W.

Bioorg Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmc.2018.08.009

Bibliografisk träff 2018-03-07

Design, synthesis and biological evaluation of anti-pancreatic cancer activity of plinabulin derivatives based on the co-crystal structure.

Fu Z, Hou Y, Ji C, Ma M, Tian Z, Deng M, Zhong L, Chu Y, Li W.

Bioorg Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmc.2018.03.005

Bibliografisk träff 2017-05-04

Click strategy using disodium salts of amino acids improves the water solubility of plinabulin and KPU-300.

Yakushiji F, Muguruma K, Hayashi Y, Shirasaka T, Kawamata R, Tanaka H, Yoshiwaka Y, Taguchi A, Takayama K, Hayashi Y.

Bioorg Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmc.2017.04.024

Bibliografisk träff 2017-02-03

Development of MBRI-001, a deuterium-substituted plinabulin derivative as a potent anti-cancer agent.

Ding Z, Cheng H, Wang S, Hou Y, Zhao J, Guan H, Li W.

Bioorg Med Chem Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmcl.2017.01.096

Bibliografisk träff 2015-11-04

Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery.

Wang Y, Zhang H, Gigant B, Yu Y, Wu Y, Chen X, Lai Q, Yang Z, Chen Q, Yang J.

FEBS J · research support, non-u.s. gov't; journal article · DOI 10.1111/febs.13555

Bibliografisk träff 2012-01-01

Prodrug study of plinabulin using a click strategy focused on the effects of a replaceable water-solubilizing moiety.

Yakushiji F, Tanaka H, Muguruma K, Iwahashi T, Yamazaki Y, Hayashi Y.

Chem Pharm Bull (Tokyo) · research support, non-u.s. gov't; journal article · DOI 10.1248/cpb.c12-00216

Bibliografisk träff 2011-11-01

Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation.

Bertelsen LB, Shen YY, Nielsen T, Stødkilde-Jørgensen H, Lloyd GK, Siemann DW, Horsman MR.

Int J Radiat Biol · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.3109/09553002.2011.605418

Bibliografisk träff 2011-09-29

Water-soluble prodrug of antimicrotubule agent plinabulin: effective strategy with click chemistry.

Yakushiji F, Tanaka H, Muguruma K, Iwahashi T, Yamazaki Y, Hayashi Y.

Chemistry · research support, non-u.s. gov't; journal article · DOI 10.1002/chem.201102293

Bibliografisk träff 2011-03-31

A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells.

Singh AV, Bandi M, Raje N, Richardson P, Palladino MA, Chauhan D, Anderson KC.

Blood · research support, u.s. gov't, p.h.s.; research support, non-u.s. gov't; research-article; research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.1182/blood-2010-12-323857

Bibliografisk träff 2011-02-16

Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel.

Millward M, Mainwaring P, Mita A, Federico K, Lloyd GK, Reddinger N, Nawrocki S, Mita M, Spear MA.

Invest New Drugs · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1007/s10637-011-9642-4

Bibliografisk träff 2010-12-01

Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas.

Mita MM, Spear MA, Yee LK, Mita AC, Heath EI, Papadopoulos KP, Federico KC, Reich SD, Romero O, Malburg L, Pilat M, Lloyd GK, Neuteboom ST, Cropp G, Ashton E, LoRusso PM.

Clin Cancer Res · clinical trial, phase i; journal article · DOI 10.1158/1078-0432.ccr-10-1096

Bibliografisk träff 2010-10-31

Tubulin photoaffinity labeling study with a plinabulin chemical probe possessing a biotin tag at the oxazole.

Yamazaki Y, Kido Y, Hidaka K, Yasui H, Kiso Y, Yakushiji F, Hayashi Y.

Bioorg Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmc.2010.10.055

Bibliografisk träff 2006-01-01

NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent.

Nicholson B, Lloyd GK, Miller BR, Palladino MA, Kiso Y, Hayashi Y, Neuteboom ST.

Anticancer Drugs · journal article · DOI 10.1097/01.cad.0000182745.01612.8a